| References: |
VXc-486, which targets gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro (MICs of 0.03 to 0.30 ug/ml and 0.08 to 5.48 u g/ml, respectively) and reduces mycobacterial burdens in lungs of infected mice in vivo.VXc-486 is active against drug-resistant isolates, has bactericidal activity, and kills intracellular and dormant M. tuberculosis bacteria in a low-oxygen environment. Furthermore, VXc-486 inhibits the growth of multiple strains of M.abscessus, M. avium complex, and M. kansasii (MICs of 0.1 to 2.0 u g/ml), as well as that of several strains of Nocardia spp. (MICs of 0.1 to 1.0 u g/ml). |
